THE ROLE OF HIGH FOLLICULAR LEVELS OF ANGIOTENSIN II AND VASCULAR ENDOTHELIAL GROWTH FACTOR IN ANTICIPATING THE DEVELOPMENT OF SEVERE OVARIAN HYPERSTIMULATION SYNDROME IN PATIENTS WITH PROPHYLACTIC CABERGOLINE THERAPY UNDERGOING AN
Angiotensin, Cabergoline
Ovarian Hyperstimulation Syndrome
Vascular endothelial growth factor
Journal
Acta endocrinologica (Bucharest, Romania : 2005)
ISSN: 1841-0987
Titre abrégé: Acta Endocrinol (Buchar)
Pays: Romania
ID NLM: 101269720
Informations de publication
Date de publication:
Historique:
entrez:
21
7
2020
pubmed:
21
7
2020
medline:
21
7
2020
Statut:
ppublish
Résumé
Severe Ovarian Hyperstimulation Syndrome (OHSS) forms with very aggressive clinical evolution are still common, despite prophylactic measures. Besides the Vascular Endothelial Growth Factor (VEGF), there are other angiogenic factors, like Renin-Angiotensin-Aldosterone System (RAS), that might be associated with this disorder. Our study aims to evaluate the role of VEGF and Angiotensin II (ANG II) in the development of early severe OHSS, in high risk patients under prophylactic Cabergoline therapy. We recruited 192 patients undergoing Follicular VEGF, ANG II, and serum VEGF levels were significantly higher in group I Our study results provide evidence of a OHSS phenotype that is more prone to undergo severe clinical forms of disease, despite treatments with VEGF receptor blockers, and show that ANG II appears to play a major role alongside VEGF, in the development of these severe forms of disease.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Severe Ovarian Hyperstimulation Syndrome (OHSS) forms with very aggressive clinical evolution are still common, despite prophylactic measures. Besides the Vascular Endothelial Growth Factor (VEGF), there are other angiogenic factors, like Renin-Angiotensin-Aldosterone System (RAS), that might be associated with this disorder. Our study aims to evaluate the role of VEGF and Angiotensin II (ANG II) in the development of early severe OHSS, in high risk patients under prophylactic Cabergoline therapy.
MATERIAL AND METHODS
METHODS
We recruited 192 patients undergoing
RESULTS
RESULTS
Follicular VEGF, ANG II, and serum VEGF levels were significantly higher in group I
CONCLUSION
CONCLUSIONS
Our study results provide evidence of a OHSS phenotype that is more prone to undergo severe clinical forms of disease, despite treatments with VEGF receptor blockers, and show that ANG II appears to play a major role alongside VEGF, in the development of these severe forms of disease.
Identifiants
pubmed: 32685035
doi: 10.4183/aeb.2020.30
pii: aeb.2020.30
pmc: PMC7364011
doi:
Types de publication
Journal Article
Langues
eng
Pagination
30-36Informations de copyright
©by Acta Endocrinologica Foundation.
Références
J Ovarian Res. 2014 Nov 26;7:106
pubmed: 25424734
Nat Cell Biol. 2006 Nov;8(11):1223-34
pubmed: 17060906
Mol Cell Endocrinol. 2013 Jan 30;365(2):223-30
pubmed: 23123737
J Assist Reprod Genet. 1994 Mar;11(3):117-22
pubmed: 7827440
Cochrane Database Syst Rev. 2017 Jan 23;1:CD012103
pubmed: 28111738
Hum Reprod. 2012 Jan;27(1):196-9
pubmed: 22016416
Hum Fertil (Camb). 2009 Mar;12(1):40-4
pubmed: 19330612
Hum Reprod. 2017 Jun 1;32(6):1318-1324
pubmed: 28402544
Reproduction. 2016 Feb;151(2):179-85
pubmed: 26612427
Fertil Steril. 2016 Dec;106(7):1634-1647
pubmed: 27678032
Int J Reprod Biomed. 2017 Feb;15(2):87-92
pubmed: 28462400
Hum Reprod. 2004 Jul;19(7):1530-8
pubmed: 15155606
Hum Reprod. 2007 Mar;22(3):669-75
pubmed: 17079244
Clin Cancer Res. 2005 Apr 1;11(7):2686-94
pubmed: 15814650
Fertil Steril. 1999 Mar;71(3):482-9
pubmed: 10065786
Fertil Steril. 2010 Mar 15;93(5):1601-8
pubmed: 19524223
Fertil Steril. 2001 Jul;76(1):98-101
pubmed: 11438326
Reprod Sci. 2016 Dec;23(12):1644-1655
pubmed: 27821561
Fertil Steril. 2011 Jan;95(1):176-81
pubmed: 20674894
Hum Reprod Update. 2010 Sep-Oct;16(5):459-66
pubmed: 20354100
Fertil Steril. 1994 Oct;62(4):731-7
pubmed: 7926081
Lancet. 1994 Jul 23;344(8917):235-6
pubmed: 7913160
Fertil Steril. 1987 Jul;48(1):57-61
pubmed: 2439386
Reprod Sci. 2008 Dec;15(10):1066-74
pubmed: 19088375
Br J Cancer. 2006 Feb 27;94(4):552-60
pubmed: 16434990
Endocr Rev. 2019 Apr 1;40(2):369-416
pubmed: 30496379
Fertil Steril. 2014 May;101(5):1411-8
pubmed: 24581579
J Ovarian Res. 2014 May 13;7:54
pubmed: 24851136
Clin Sci (Lond). 2012 Sep;123(5):273-84
pubmed: 22590974
Fertil Steril. 2008 Sep;90(3):531-6
pubmed: 18001715
J Clin Endocrinol Metab. 2002 Jul;87(7):3300-8
pubmed: 12107240
Fertil Steril. 2000 Oct;74(4):809-12
pubmed: 11020528
Acta Obstet Gynecol Scand. 2009;88(12):1373-81
pubmed: 19878052
Fertil Steril. 2013 May;99(6):1749-58
pubmed: 23465821